Summit Therapeutics (NASDAQ:SMMT) traded higher for the fifth straight session on Thursday as investors continued to cheer the latest trial data for its lead asset, ivonescimab, which indicated an outperformance against tislelizumab, a PD-1 inhibitor marketed by BeiGene...
Price: (as of - Details)
The stock market offers endless opportunities for those who understand its dynamics. Whether you are a beginner or an experienced trader, mastering different trading strategies is key to financial success. This...
Price: (as of - Details)
My main purpose of starting this book series is that each and every trader should be able to create his own trading ideas and strategies. I have directly shared the rules...
